From breathless playdates to emergency rooms, Jessie James Decker shares the emotional journey behind her son’s life changing ...
Parents are becoming more lenient with their kids swearing. A University of Michigan survey found that fewer than half of ...
New research reveals that depression linked to asthma may have a different biological basis than primary depression ...
The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult and pediatric patients aged ...
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...
A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...
Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won European regulatory approval for two inflammatory disease indications. The European Medicines Agency's ...
Please provide your email address to receive an email when new articles are posted on . The COVID-adjusted annualized asthma exacerbation rate dropped by 46%. Mean cumulative oral corticosteroid dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results